Erratum: Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review

In the review by Monach et al in the January 2010 issue of Arthritis & Rheumatism (pages 9–21), there were several errors in the text of the fourth paragraph on page 15. The paragraph should have read as follows: “The recommended dosing of IV mesna is a total dose equal to 60% (weight/weight) of the total cyclophosphamide dose, in the form of 3 equal doses of mesna (20% each of the total dose), with the first dose administered 15–30 minutes prior to cyclophosphamide and the others administered 4 hours and 8 hours following cyclophosphamide (67). When mesna is given orally, the dose should be equal to 40% of the cyclophosphamide dose (oral or IV), based on the 50% oral bioavailability of mesna. For convenience, a combination of IV and oral doses can be given: an initial IV dose (equal to 20% of the cyclophosphamide dose) followed by 2 oral doses (each equal to 40% of the cyclophosphamide dose). If the first dose of mesna is administered orally, it should be given 2 hours before cyclophosphamide (oral or IV), but the second and third oral doses can still be given 4 hours and 8 hours after cyclophosphamide, as with IV mesna dosing.”

We regret the errors.